Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > A little movement on a patent

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jun 24, 2022 11:13pm

320 Views

Post# 34781948

RE:A little movement on a patent

And it looks like the cannabinoid one has come back to life again as well.

16/365,148

METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF A CANNABINOID RECEPTOR AGONIST AND RADIATION THERAPY

T1081/20069

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Code	Document Description	Document Category	Page Count
06-24-2022	RCEX	Request for Continued Examination (RCE)	PROSECUTION	3
06-24-2022	WFEE	Fee Worksheet (SB06)	PROSECUTION	2
06-24-2022	N417	Electronic Filing System(EFS) Acknowledgment Receipt	PROSECUTION	3
06-24-2022	XT/	Extension of Time	PROSECUTION	1
06-24-2022	A.NE	Response After Final Action	PROSECUTION	1
06-24-2022	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	3
06-24-2022	AF/D.132	Affidavit-traversing rejections or objections rule 132